Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3572750 | 0.93 | PTGDR2 (0.39) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL13547357 | 0.89 | PTGDR2 (0.48) | HPGDLMNAPTGDR2 | |
| SCHEMBL2771246 | 0.82 | PTGDR2 (0.46) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL2774269 | 0.72 | PTGDR2 (0.51) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL3564465 | 0.71 | PTGDR2 (0.52) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL2769764 | 0.71 | PTGDR2 (0.57) | HPGDLMNAPTGDR2TP53RXFP1 | |
| SCHEMBL2769710 | 0.69 | PTGDR2 (0.66) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL3579992 | 0.69 | PTGDR2 (0.48) | ALDH1A1MEN1KMT2AGAALMNA | |
| SCHEMBL3572270 | 0.69 | PTGDR2 (0.80) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL3962109 | 0.67 | PTGDR2 (0.39) | ALDH1A1MEN1KMT2AGAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| CN-101605544-A | CRTH2 antagonists | ARGENTA INV CO LTD (GB) | 2009-12-16 | — | — | CN | disclosed |
| EP-2094266-A1 | CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074966-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | HRH2, MDH2, HRH1 | ALDH1A1 831/4885MEN1 2421/4885KMT2A 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.